P32 Phase III studies of crenezumab in early (prodromal-to-mild) Alzheimers disease (CREAD/CREAD2): Biomarker results

Saved in:
Bibliographic Details
Published in:Clinical neurophysiology 2020-04, Vol.131 (4), p.e194-e195
Main Authors: Bittner, T., Duning, T., Rabe, C., Clayton, D., Quartino, A., Bohorquez, S. Sanabria, Hu, N., Rabbia, M., Shimizu, H., Eichenlaub, U., Smith, J., Honigberg, L., Selkoe, D.J., Ostrowitzki, S.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1388-2457
1872-8952
DOI:10.1016/j.clinph.2019.12.038